**Appendix**

**Table 1: Cross-Tabulation of Types of CT Tests Offered in Each Year (N=236)**

|  |  |  |  |
| --- | --- | --- | --- |
| **2013** | **2015** | | |
| **Type of CT Test** | **In-House** | **Referral** | **Not Offered/ Not Answered** |
| Culture |  |  |  |
| **In-House N (%)** | 14 (63.6%) | 5 (22.7%) | 3 (13.6%) |
| **Referral N (%)** | 5 (3.0%) | 128 (75.7%) | 36 (21.3%) |
| **Not Offered N (%)** | 3 (7.0%) | 10 (23.3%) | 30 (69.8%) |
| DFA |  |  |  |
| **In-House N (%)** | 6 (54.5%) | 2 (18.2%) | 3 (27.3%) |
| **Referral N (%)** | 1 (0.8%) | 70 (58.8%) | 48 (40.3%) |
| **Not Offered N (%)** | 1 (1.0%) | 27 (26.0%) | 76 (73.1%) |
| Hybrid Capture |  |  |  |
| **In-House N (%)** | 1 (50.0%) | 0 (0.0%) | 1 (50.0%) |
| **Referral N (%)** | 0 (0.0%) | 49 (59.8%) | 33 (40.2%) |
| **Not Offered N (%)** | 1 (0.7%) | 30 (20.0%) | 119 (79.3%) |
| NAAT |  |  |  |
| **In-House N (%)** | 122 (93.8%) | 7 (5.4%) | 1 (0.7%) |
| **Referral N (%)** | 11 (11.5%) | 80 (83.3%) | 5 (5.2%) |
| **Not Offered N (%)** | 1 (11.1%) | 6 (66.7%) | 2 (22.2%) |
| Rapid Test |  |  |  |
| **In-House N (%)** | 2 (25.0%) | 1 (12.5%) | 5 (62.5%) |
| **Referral N (%)** | 1 (1.8%) | 30 (53.6%) | 25 (44.6%) |
| **Not Offered N (%)** | 3 (1.8%) | 29 (17.2%) | 137 (81.1%) |
| MIF |  |  |  |
| **In-House N (%)** | 1 (50.0%) | 0 (0.0%) | 1 (50.0%) |
| **Referral N (%)** | 0 (0.0%) | 45 (57.0%) | 34 (43.0%) |
| **Not Offered N (%)** | 1 (0.7%) | 28 (18.3%) | 124 (81.0%) |
| EIA |  |  |  |
| **In-House N (%)** | 0 (0.0%) | 0 (0.0%) | 2 (100.0%) |
| **Referral N (%)** | 3 (3.5%) | 52 (60.5%) | 31 (36.0%) |
| **Not Offered N (%)** | 4 (2.7%) | 27 (18.5%) | 115 (78.8%) |
| CF |  |  |  |
| **In-House N (%)** | 0 (0.0%) | 1 (100.0%) | 0 (0.0%) |
| **Referral N (%)** | 0 (0.0%) | 49 (62.8%) | 29 (37.2%) |
| **Not Offered N (%)** | 0 (0.0%) | 28 (18.1%) | 127 (81.9%) |
| Other |  |  |  |
| **In-House N (%)** | 0 (0.0%) | 0 (0.0%) | 4 (100.0%) |
| **Referral N (%)** | 0 (0.0%) | 0 (0.0%) | 8 (100.0%) |
| **Not Offered N (%)** | 4 (1.8%) | 19 (8.7%) | 196 (89.5%) |

**Table 2: Cross-tabulation of Types of GC Tests Offered in Each Year (N=236)**

|  |  |  |  |
| --- | --- | --- | --- |
| **2013** | **2015** | | |
| **Type of GC Test** | **In-House** | **Referral** | **Not Offered** |
| Culture |  |  |  |
| **In-House N (%)** | 167 (92.8%) | 8 (4.4%) | 5 (2.8%) |
| **Referral N (%)** | 5 (12.8%) | 27 (69.2%) | 7 (17.9%) |
| **Not Offered N (%)** | 3 (17.6%) | 3 (17.6%) | 11 (64.7%) |
| Gramstain |  |  |  |
| **In-House N (%)** | 135 (79.4%) | 12 (7.1%) | 23 (13.5%) |
| **Referral N (%)** | 7 (29.2%) | 11 (45.8%) | 6 (25.0%) |
| **Not Offered N (%)** | 11 (26.2%) | 4 (9.5%) | 27 (64.3%) |
| Hybrid Capture |  |  |  |
| **In-House N (%)** | 1 (0.0%) | 0 (0.0%) | 1 (50.0%) |
| **Referral N (%)** | 0 (0.0%) | 44 (58.7%) | 31 (41.3%) |
| **Not Offered N (%)** | 0 (0.0%) | 33 (20.8%) | 126 (79.2%) |
| NAAT |  |  |  |
| **In-House N (%)** | 124 (94.7%) | 7 (5.3%) | 0 (0.0%) |
| **Referral N (%)** | 10 (10.1%) | 85 (85.9%) | 4 (4.0%) |
| **Not Offered N (%)** | 2 (33.3%) | 3 (50.0%) | 1 (16.7%) |
| Rapid Test |  |  |  |
| **In-House N (%)** | 1 (33.3%) | 0 (0.0%) | 2 (66.7%) |
| **Referral N (%)** | 3 (5.3%) | 26 (45.6%) | 28 (49.1%) |
| **Not Offered N (%)** | 1 (0.6%) | 33 (18.8%) | 142 (80.7%) |
| EIA |  |  |  |
| **In-House N (%)** | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| **Referral N (%)** | 0 (0.0%) | 44 (54.3%) | 37 (45.7%) |
| **Not Offered N (%)** | 0 (0.0%) | 31 (20.0%) | 124 (80.0%) |
| Other |  |  |  |
| **In-House N (%)** | 0 (0.0%) | 0 (0.0%) | 2 (100.0%) |
| **Referral N (%)** | 0 (0.0%) | 0 (0.0%) | 4 (100.0%) |
| **Not Offered N (%)** | 3 (1.3%) | 18 (7.8%) | 209 (90.9%) |

**Table 3: CT Primary Test Manufacturer (N=236)** *\*Restricted by labs conducting any CT testing in-house*

|  |  |  |
| --- | --- | --- |
|  | **2013** | **2015** |
| **Manufacturer** | **N (%)** | **N (%)** |
| Culture | 0 (0.0%) | 1 (0.4%) |
| Abbott | 1 (0.4%) | 1 (0.4%) |
| BD | 25 (10.6%) | 15 (6.4%) |
| Hologic | 58 (24.6%) | 52 (22.0%) |
| Roche | 20 (8.5%) | 22 (9.3%) |
| Qiagen | 1 (0.4%) | 0 (0.0%) |
| Cepheid | 26 (11.0%) | 41 (17.4%) |
| Bio-Rad | 0 (0.0%) | 1 (0.4%) |
| Lab PCR | 0 (0.0%) | 1 (0.4%) |
| Quidel | 0 (0.0%) | 6 (2.5%) |
| Other | 13 (5.5%) | 4 (1.7%) |
| Does not conduct in-house testing or did not answer | 92 (39.0%) | 92 (39.0%) |
| *\*Note: “Lab PCR” is a laboratory developed test used by the lab in-house.* | | |

**Table 4: GC Primary Test Manufacturer (N=236)**

|  |  |  |
| --- | --- | --- |
|  | **2013** | **2015** |
| **Manufacturer** | **N (%)** | **N (%)** |
| Culture | 25 (10.6%) | 42 (17.8%) |
| Abbott | 1 (0.4%) | 1 (0.4%) |
| BD | 31 (13.1%) | 18 (7.6%) |
| Hologic | 77 (32.6%) | 66 (28.0%) |
| Roche | 16 (6.8%) | 24 (10.2%) |
| Qiagen | 1 (0.4%) | 0 (0.0%) |
| Cepheid | 26 (11.0%) | 42 (17.8%) |
| Lab PCR | 0 (0.0%) | 1 (0.4%) |
| Other | 35 (14.8%) | 11 (4.7%) |
| Does not conduct in-house testing or did not answer | 24 (10.2%) | 31 (13.1%) |
| *\*Note: “Lab PCR” is a laboratory developed test used by the lab in-house.* | | |